MIRA INFORM REPORT

 

 

Report Date :

29.05.2012

 

IDENTIFICATION DETAILS

 

Name :

COSMA SPA

 

 

Registered Office :

Via Colleoni 15/17, Ciserano, 24040

 

 

Country :

Italy

 

 

Financials (as on) :

31.12.2010

 

 

Date of Incorporation :

23.012.1977

 

 

Com. Reg. No.:

00714610169

 

 

Legal Form :

Public Subsidiary

 

 

Line of Business :

Engaged in production of medicinally active substances to be used for their pharmacological properties in the manufacture of medicaments; and processing of blood

 

 

No. of Employees :

68

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

No complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Italy

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Company name and address

 

Cosma SpA

 

 

 

Via Colleoni 15/17

 

 

Ciserano, 24040

Italy

 

Fax:

+39 0354 820501

 

Employees:

68

Company Type:

Public Subsidiary

Corporate Family:

4 Companies

Ultimate Parent:

MEDINCO SPA

 

 

Incorporation Date:

23-Dec-1977

 

 

 

 

 

 

 

Fiscal Year End:

31-Dec-2010

Reporting Currency:

Euro

Annual Sales:

26.9

Total Assets:

24.9

 

 

 

 

 

 

 

Business Description

 

 

 

COSMA SPA is primarily engaged in production of medicinally active substances to be used for their pharmacological properties in the manufacture of medicaments; and processing of blood. This class also includes: manufacture of chemically pure sugars; and processing of glands and manufacture of extracts of glands, etc.

 

 

Industry

 

 

 

Industry

Biotechnology and Drugs

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

NACE 2002:

2441 - Manufacture of basic pharmaceutical products

NAICS 2002:

32541 - Pharmaceutical and Medicine Manufacturing

UK SIC 2003:

2441 - Manufacture of basic pharmaceutical products

US SIC 1987:

2833 - Medicinal Chemicals and Botanical Products

 

 

Key Executives

 

 

 

 

Name

Title

 

Claudio Rebuzzini

President

 

Roberto Angelo Fusco

Member of the board

 

Maria Cristina Rebuzzini

Member of the board

 

 

News

 

 

Title

Date

Gwinnett man charged with making illegal liquor
Atlanta Journal-Constitution (GA) (332 Words)

18-May-2012

BRIEF: Gwinnett man charged with making illegal liquor
Atlanta Journal-Constitution (GA) (174 Words)

17-May-2012

Magna Announces First Quarter Results
Canada Newswire (17740 Words)

10-May-2012

Residents' wish list
Heidelberger (Australia) (226 Words)

18-Apr-2012

Edwina Tops wins Qatar GCT
Qatar Tribune (500 Words)

8-Apr-2012

 

 

Registered No.(ITA)

 

00714610169

 

1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7550783

2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7454064

 

 

Corporate Overview

 

 

Location
Via Colleoni 15/17
Ciserano, 24040
Italy

 

Fax:

+39 0354 820501

 

Suggest Company URL

 

Sales EUR(mil):

20.3

Assets EUR(mil):

18.6

Employees:

68

Fiscal Year End:

31-Dec-2010

 

 

 

Industry:

Biotechnology and Drugs

Incorporation Date:

23-Dec-1977

Company Type:

Public Subsidiary

Quoted Status:

Not Quoted

Registered No.(ITA):

00714610169

 

Member of the board:

Roberto Angelo Fusco

 

 

Industry Codes

 

 

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

3323

-

Industrial and Agricultural Chemical Product Wholesaling

 

NACE 2002 Codes:

5155

-

Wholesale of chemical products

2441

-

Manufacture of basic pharmaceutical products

 

NAICS 2002 Codes:

32541

-

Pharmaceutical and Medicine Manufacturing

4246

-

Chemical and Allied Products Merchant Wholesalers

 

US SIC 1987:

2833

-

Medicinal Chemicals and Botanical Products

516

-

Chemicals and Allied Products

 

UK SIC 2003:

5155

-

Wholesale of chemical products

2441

-

Manufacture of basic pharmaceutical products

 

 

Business Description

 

 

COSMA SPA is primarily engaged in production of medicinally active substances to be used for their pharmacological properties in the manufacture of medicaments; and processing of blood. This class also includes: manufacture of chemically pure sugars; and processing of glands and manufacture of extracts of glands, etc.

 

 

 

 

 

 

Financial Data

 

 

Financials in:

EUR(mil)

 

Revenue:

20.3

Assets:

18.6

Current Assets:

10.9

 

Total Liabilities:

18.6

 

Net Worth:

13.4

 

 

 

Date of Financial Data:

31-Dec-2010

 

1 Year Growth

-5.5%

NA

 

 

Key Corporate Relationships

 

 

Bank:

Credito Bergamasco Ag, Ubi Banca Popolare di Bergamo Ag, Intesa Sanpaolo Ag

 

 

 

 

 

Corporate Structure News

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

Source

MEDINCO SPA

Parent

 

 

 

 

 

 

Cosma SpA

Subsidiary

Ciserano, Bergamo

Italy

Biotechnology and Drugs

26.9

68

D&B

Amsa Anonima Materie Sintetiche Ed Affini SpA

Subsidiary

Milano, Milano

Italy

Biotechnology and Drugs

30.9

59

D&B

C.F.M. Co. Farmaceutica Milanese SpA

Subsidiary

Milano, Milano

Italy

Chemical Manufacturing

13.9

20

D&B

 

 

Executives Report

 

 

Board of Directors

 

Name

Title

Function

 

Roberto Angelo Fusco

 

Member of the board

Director/Board Member

 

Maria Cristina Rebuzzini

 

Member of the board

Director/Board Member

 

 

Executives

 

Name

Title

Function

 

Claudio Rebuzzini

 

President

President

 

 

 

Annual Profit & Loss

 

 

 

 

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate (Period Average)

0.755078

0.719047

0.683679

Consolidated

No

No

No

 

 

 

 

Total income

26.4

31.4

33.0

Net sales

26.9

30.0

32.0

Other operating income

0.1

0.1

0.1

Raw materials and consumables employed

11.1

12.5

15.0

Other expenses

6.5

7.1

8.0

Total payroll costs

5.4

5.8

5.9

Fixed asset depreciation and amortisation

1.3

1.4

1.4

Other operating costs

0.3

0.3

0.2

Net operating income

1.9

4.4

2.5

Total financial income

0.2

-0.2

0.5

Total expenses

0.0

0.0

0.0

Profit before tax

2.0

4.2

3.0

Extraordinary result

-0.1

0.3

0.1

Profit after extraordinary items and before tax

2.0

4.5

3.1

Total taxation

0.5

1.5

1.2

Net profit

1.5

3.0

1.9

 


Annual Balance Sheet

 

 

 

Financials in: USD (mil)

 

 

 

31-Dec-2010

31-Dec-2009

31-Dec-2008

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.745406

0.696986

0.719399

Consolidated

No

No

No

 

 

 

 

Total stockholders equity

18.0

18.4

16.2

Provision for risks

0.3

0.3

0.2

Provision for pensions

0.6

0.6

0.6

Trade creditors

4.6

5.3

6.2

Other current liabilities

1.4

2.1

2.2

Total current liabilities

6.1

7.4

8.4

Total liabilities (including net worth)

24.9

26.7

25.4

Intangibles

0.0

0.0

0.0

Buildings

3.3

3.6

5.9

Total tangible fixed assets

8.1

7.4

7.9

Long-term investments

1.5

1.6

1.5

Total financial assets

2.2

2.3

2.2

Receivables due after 1 year

-

-

0.0

Total non-current assets

10.3

9.8

10.1

Finished goods

4.9

5.9

4.3

Net stocks and work in progress

7.3

8.3

7.2

Trade debtors

4.0

4.9

5.2

Other receivables

0.8

0.4

0.3

Cash and liquid assets

2.6

3.2

2.6

Accruals

0.0

0.0

0.0

Total current assets

14.7

16.9

15.2

Total assets

24.9

26.7

25.4




Annual Ratios

 

 

 

Financials in: USD (mil)

 

 

 

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.745406

0.696986

0.719399

Consolidated

No

No

No

 

 

 

 

Current ratio

2.40

2.30

1.80

Quick ratio

1.20

1.20

1.00

Current liabilities to net worth

0.00%

0.00%

0.01%

Sales per employee

0.34

0.38

0.38

Profit per employee

0.02

0.06

0.04

Average wage per employee

0.07

0.07

0.07

Net worth

18.0

18.4

16.2

Number of employees

60

56

56

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.55.26

UK Pound

1

Rs.86.80

Euro

1

Rs.69.63

 

 

INFORMATION DETAILS

 

Report Prepared by :

PDT

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.